- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Selected Parameters for Quality Assessment of Platelet Products Available for Transfusion Purpose at Oncology Centers in Basra, Iraq | ||
| The Medical Journal of Basrah University | ||
| Article 7, Volume 42, Issue 1, June 2024, Pages 52-63 PDF (531.06 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.33762/mjbu.2024.147186.1200 | ||
| Authors | ||
| Rasha Ahmed Talib* 1; Sadiq Khalaf Ali2 | ||
| 1Basra health directorate, Ministery of health, Iraq. | ||
| 2Department of Pathology, Al-Zahraa College of Medicine / University of Basrah | ||
| Abstract | ||
| Background: Platelet transfusion is significantly involved in the treatment of oncology patients since the disease process as well as many therapeutic agents can induce significant thrombocytopenia. Many variables regarding platelet products were studied over the years to determine the quality of platelet products. The study aimed to assess the quality of platelet-rich plasma platelet concentrate, and apheresis platelet concentrate that are available for transfusion in oncology centres. Subjects and Methods: A cross-sectional study was conducted at the main blood bank in Basra, Iraq, the blood bank branch in Basra Specialized Children’s Hospital, and oncology centres in Basra between May 2023 and September 2023. One hundred fifty apheresis platelet concentrate units and 150 Platelet-rich plasma platelet concentrate units were assessed for their in vitro quality by assessing the volume of platelet concentrate units, platelet count per unit, and residual white blood cell per unit. Fifty patients were assessed for their response to platelet transfusion; half received PRP-PC, and the other half received apheresis platelet concentrate. Results: Apheresis-PC units met volume and residual WBC criteria (98.08%, 90.38%) better than PRP-PC (61.33%, 5.60%). Final scoring showed 4.6% PRP and 15.3% apheresis-PC, scoring 3. Patient response analysis revealed increased platelet count after transfusion, with a higher number of transfused units for PRP-PC (13 ± 5.28 units) vs. apheresis-PC (1 ± 0.28 units). Recovery was > 20% for 80% of apheresis-PC and 56% for PRP-PC. Conclusion: Apheresis-PC outperformed PRP-PC in meeting quality standards. Apheresis-PC had a higher platelet count and lower WBC contamination, which makes it a better choice for platelet transfusion to reduce recipient exposure to multiple donors. Recipient differences in age, weight, blood volume, and type of malignancy didn't affect the transfusion response. | ||
| Keywords | ||
| Keywords: Quality Assessment; Platelet Products; Blood Transfusion; Oncology; Basra; Iraq | ||
|
Statistics Article View: 4,180 PDF Download: 181 |
||